Author

Frank Stappenbeck

Max Biopharma (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Atsuto Kusunoki· 1 shared Farhad ParhamiiD· 1 shared Feng Wang· 1 shared Hirofumi OhashiiD· 1 shared Kaho Shionoya· 1 shared Kazuhiko KatayamaiD· 1 shared Koichi WatashiiD· 1 shared Makoto Nagano· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Atsuto Kusunoki

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologybioRxivPreprintFeb 5, 2026

Disruption of the NTCP-EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry

Atsuto Kusunoki, Kaho Shionoya, Frank Stappenbeck…·Koichi Watashi

This study identifies Oxy229, a compound that disrupts the NTCP-EGFR receptor complex, selectively inhibiting HBV and HDV entry without affecting NTCP or EGFR physiological functions.

DOI 10.64898/2026.02.05.703960

humanexperimental assay

𝕏 PostBluesky